--In a preclinical model of psoriasis, the efficacy of oral small molecule REX-7117 was comparable to an anti-IL-17A biologic SAN DIEGO, May 17, 2024 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in ...

VVD-130850 is an investigational oral small molecule inhibitor of STAT3 transcription factor developed for treatment of advanced solid and hematologic tumors as a single agent and in combination with ...

-REX-7117 is an oral, potent and selective STAT3 SH2 domain inhibitor, which demonstrated strong efficacy in an in vivo model of inflammatory arthritis -STAT3 inhibition does not impair the interferon ...

Scientists from Recludix Pharma Inc. presented the preclinical characterization of REX-7117, an orally available, reversible, SH2 domain-targeting STAT3 inhibitor, being developed for the treatment of ...

Vividion Therapeutics Inc. has patented 2-azaspiro [3.3]heptane derivatives acting as signal transducer and activator of transcription 3 (STAT3) inhibitors potentially useful for the treatment of ...

On track for topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma (HCC) in H1 2026 Results from healthy volunteer study of its next-generation STAT3 inhibitor, TTI-109, expected in ...

ARTEMIS-001: Phase 1 study of HS-20093, a B7-H3–targeting antibody-drug conjugate, in patients with advanced solid tumor. Preliminary safety and efficacy of tinengotinib tablets as monotherapy and ...

Santa Cruz Biotechnology is a world leader in the development of products for the biomedical research market. Over the past 30+ years, the Company has focused on the ongoing development of research ...

Schematic diagram of the IL-6/JAK/STAT3 signaling pathway activation in mouse liver macrophages. IRs, inhibitory receptors (IRs); ICIs, immune checkpoint inhibitors; IL-6, interleukin-6; ALT, alanine ...